Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …

Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …

PURPOSE:: To assess the overall and progression-free survival, response rate, and toxicity
of combined docetaxel and celecoxib in the treatment of patients with non-small cell lung …

Background Increased expression of cyclooxygenase-2 (COX-2) is common in non-small
cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and …

Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …

PURPOSE The selection of effective schedules of treatment for metastatic non-small cell
lung cancer still remains a challenge for the oncologist. The present multicentric phase II …

Accumulating preclinical and clinical studies have shown that cyclooxygenase-2 (COX-2)
inhibitor has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III …

Abstract Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG)
synthesis and is overexpressed in 70% to 90% of non–small cell lung cancers (NSCLC) …

Background The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib,
combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains …